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A B S T R A C T
Hepatocellular carcinoma is the fifth most common cancer in men and the seventh in women, 
as is diagnosed in more than half a million individuals worldwide every year. In Portugal, its 
incidence and mortality rates are low compared to other types of cancers. In Brazil, in the 
city of São Paulo, according to data released by the Brazilian Unified Health System (Sistema 
Único de Saúde – SUS), the incidence of primary liver cancer was 2.07/100,000 inhabitants. 
Although the vast majority of cases (85%) mainly affect developing countries, especially 
where infection by hepatitis B virus (HBV) is endemic, the incidence in developed countries 
is increasing. This pathology is associated with several risk factors, not only environmental 
but also genetic, generating an increasing interest in attaining a better understanding of this 
disease, which is still associated with very late diagnosis and poor prognosis. Of the available 
treatments, few patients benefit from their scanty advantages, increasingly stimulating 
research of new forms of treatment against this disease. This review aimed to briefly but 
fully identify risk factors, molecular and biochemical pathways, pathophysiology, diagnosis, 
and possible clinical approaches of hepatocellular carcinoma. 
© 2012 Elsevier Editora Ltda. 
Carcinoma hepatocelular: epidemiologia, biologia, diagnóstico e terapias
R E S U M O
O carcinoma hepatocelular é o quinto tipo de câncer mais comum em homens e o sétimo 
em mulheres, diagnosticado todos os anos em mais de meio milhão de pessoas por todo 
o mundo. Em Portugal, sua incidência e mortalidade são baixas, comparativamente a 
outros tipos de cânceres. No Brasil, no município de São Paulo, segundo dados divulgados 
Palavras-chave:
Carcinoma hepatocelular
Terapia
Diagnóstico
 
Este é um artigo Open Access sob a licença de CC BY-NC-ND
Este é um artigo Open Access sob a licença de CC BY-NC-ND
 REV ASSOC MED BRAS. 2013;59(5):514-524 515
pelo Sistema Único de Saúde (SUS), a incidência do câncer primário de fígado foi de 
2,07/100.000 habitantes. Apesar de a grande maioria dos casos (85%) afetar principalmente 
países em desenvolvimento, sobretudo onde a infeção pelo vírus de hepatite B (HVB) é 
endêmica, a incidência em países desenvolvidos é cada vez maior. Esta patologia está 
associada a inúmeros fatores de risco não só ambientais, mas também genéticos, os quais, 
cada vez mais, despertam interesse na procura pelo melhor conhecimento da patologia, muito 
associada ainda a diagnósticos tardios e maus prognósticos. Dos tratamentos disponíveis, 
poucos doentes são aqueles que usufruem das suas escassas vantagens, estimulando cada 
vez mais a pesquisa de novas formas de terapêutica. Esta revisão pretende, de forma breve 
mas completa, identificar fatores de risco, vias moleculares e bioquímicas, fisiopatologia, 
diagnóstico e possíveis abordagens clínicas do carcinoma hepatocelular.
© 2012 Elsevier Editora Ltda. 
Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the primary liver cancer, 
that is to say, derived from primary liver cells. As in all 
cancers, it appears when mutations in the genes of a cell make 
uncontrolled growth possible. This mutation can be caused 
by external agents, such as hepatitis virus, or by excessive 
multiplication of cells, as in chronic regeneration in chronic 
hepatitis, which increases the risk of replication errors in the 
genes. HCC is typically aggressive, with a high rate of death 
after symptom onset (most commonly jaundice and/or ascites). 
If detected only in the symptomatic phase, the patient has 
an untreated mean life expectancy of less than one month; 
even at this stage, the available treatments are limited and 
ineffective.
HCC represents 70-85% of primary liver cancers, and is the 
most frequently observed primary malignant liver tumors 
worldwide,; cholangiocarcinoma, which originates from 
cholangiocytes, i.e., the epithelial cells lining the bile ducts, 
constitute 10-15% of primary hepatic malignancies. The 
remaining 5% are uncommon tumors such as primary liver 
angiosarcoma, hepatic epithelioid hemangioendothelioma, 
hemangiopericytoma, or primary hepatic lymphoma. 
Annually, HCC is diagnosed in more than half a million 
people worldwide. The latest figures showed an estimated 
748,300 new cases of HCC and 695,900 deaths caused by this 
disease. In Europe, 60,200 new cases were diagnosed in 2008, 
making this type of cancer the fifth most common in men and 
the seventh in women1,2 (Fig. 1).
In Portugal, the incidence rate of this disease is low 
compared with other types of cancer, according to data 
from GLOBOCAN 2008, representing 1.1% of all cancer types. 
Regarding mortality associated with this type of pathology, 
it is responsible for 2% of all cancer-related deaths3; in the 
year 2011, according to the National Institute of Statistics of 
Portugal, 979 deaths due to malignant liver and intrahepatic 
bile duct neoplasms were recorded, 84 more cases than in the 
previous year.4
The World Health Organization (WHO) indicates HCC as 
the second leading cause of cancer-related death in humans 
due to its high incidence in the East, in areas of Africa, and 
in the Western Pacific. In Brazil, the incidence of HCC is low, 
while higher in some states such as Espírito Santo and Bahia. 
In the state of São Paulo, HCC is the fifth in frequency among 
digestive tract tumors, according to the Brazilian Association 
of Liver Transplants and Liver Disease Carriers. 
Approximately 85% of the cases occur in developing 
countries, and the highest incidence rates are described in 
regions where hepatitis B virus (HBV) infection is endemic: 
Southeast Asia and sub-Saharan Africa. HCC rarely occurs 
before 40 years of age and reaches its peak at approximately 
70 years of age. The prevalence rate of liver cancer among men 
is two to four times higher than among females. 
HCC related to hepatitis C virus (HCV) infection has become 
the fastest-growing cause of the disease in the United States, 
contributing to the rising incidence of HCC in that country, 
which has tripled; the five-year rate survival remained below 
12%.
Epidemiological data regarding the HCC in some countries, 
such as Brazil and Portugal, are still scarce and dispersed, 
making the organization and planning of health-promoting 
activities with an impact on prevention and early diagnosis 
of this pathology difficult. According to data released by the 
Brazilian Unified Health System (Sistema Único de Saúde – 
SUS), the incidence of primary liver cancer in the city of São 
Paulo, Brazil, was 2.07/100,000 inhabitants. The mean age of 
patients was 54.7 years, with a male/female ratio of 3.4:1. 
HBV surface antigen (HBsAg) positivity was 41.6%, anti-HCV 
positivity was 26.9%, presence of chronic alcoholism was 37%, 
and cirrhosis was 71.2%.5
Estimates made by GLOBOCAN for 2008 suggest that the 
incidence rate is 3.5/100,000 for males and 1.2/100,000 for 
females, resulting in 477 new cases per year. Mortality rates are, 
according to the same source, 3.4/100,000 and 1.1/100,000 for 
males and females, respectively. 
Risk factors
The main risk factors for HCC include infection by HBV 
and HCV, liver diseases caused by alcohol consumption, 
aflatoxin exposure, and mainly non-alcoholic fatty liver 
disease6 (NAFLD). Less common causes include hereditary 
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hemochromatosis (HH), alpha-1-antitrypsin deficiency, 
autoimmune hepatitis, certain porphyria types, and Wilson’s 
disease. The distribution of these risk factors among patients 
with HCC is highly variable and depends on the geographic 
region, race, and ethnic group.7
Most of these risk factors lead to the onset and progression 
of cirrhosis, which is present in 80-90% of patients with HCC. 
The cumulative risk at five years for patients with cirrhosis 
to develop HCC varies between 5% and 30%, depending on 
the cause, with the greatest risk among those infected with 
HCV, those with specific risk due to geographic region or 
ethnic group (17% in USA and 30% in Japan, for instance), and 
the stage of cirrhosis; patients with decompensated disease 
present the greatest risk.8
Worldwide, approximately 50% of all adult patients 
with HCC have chronic HBV infection, whereas in children 
Fig. 1 – Regional variation in incidence rates of hepatocellular carcinoma (standardized age). The incidence rates shown 
(number of cases per 100,000 inhabitants) are for both genders and all age ranges.106,107
Cases/100,000 individuals
≤ 2.5
≤ 4.0
≤ 6.0
≤ 9.3
≤ 9.4
Fig. 2 – Molecular events in the development of hepatocellular carcinoma stages.39,46-48,50,53-56,58-61,63,65-67,70-74 HCC, 
hepatocellular carcinoma; HCV, hepatitis C virus; TGF, transforming growth factor; VEGF, vascular endothelial growth factor.
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this association occurs in virtually all cases. In endemic 
areas of Asia and Africa, where HBV infection is vertical, 
approximately 90% of those infected undergo chronic evolution 
of the disease, with frequent virus integration into the host 
DNA.9,10 The association between HBV and cancer varies 
greatly depending on the country and the types of laboratory 
tests used to diagnose the disease11; this scenario is changing 
with the emergence of new diagnostic techniques, especially 
polymerase chain reaction (PCR). 
Although HBV can cause HCC in the absence of cirrhosis, 
between 70% and 80% of the patients present liver cirrhosis as 
a consequence of HBV infection. The risk of HCC in individuals 
with HBV infection is higher in males, the elderly, those 
with long-term exposure to the virus, family history of HCC, 
exposure to aflatoxin-type mycotoxins, alcohol or tobacco 
consumption, HCV or hepatitis delta virus (HDV) co-infection, 
high levels of HBV viral replication, and/or infection by HBV 
genotype C.10,12-15 The estimated risk of HCC is 15-20 times 
higher among individuals infected with HCV compared with 
the non-infected; most of the additional risk is limited to those 
with advanced liver fibrosis or cirrhosis.16
An evolutionary molecular analysis study demonstrated 
that HCV infection occurred in a large number of young adults 
in Japan in the 1920s, in southern Europe in the 1940s, and in 
North America in the 1960s and 1970s. These cases in North 
America occurred as a result of the sharing of contaminated 
needles among drug addicts and due to blood transfusions17; 
the first case was described in 1989.
HCV infection markers are found in 80-90% of patients 
with HCC in Japan, 44-66% in Italy, and 30-50% in the United 
States.7 Risk factors for HCC among individuals infected with 
HCV include older age at the time of infection, male gender, 
co-infection with the human immunodeficiency virus (HIV) 
or HBV, and probably diabetes or obesity.18-21 The prolonged 
and abusive consumption of alcohol, defined as daily ingestion 
of 40 to 60 g of beverages containing 13.7 g of alcohol is a 
well-established risk factor for HCC, whether independently, 
with a 1.5-2.0 times increased risk , or combined with other 
risk factors, such as infection by HCV, or, to a lesser extent, 
infection with HBV.16
The development of effective screening methods in 
blood donors regarding the presence of HBV in the 1980s 
and of HCV in the 1990s drastically reduced the incidence 
of transfusion-related viral hepatitis, reducing its rates 
from 33% to 0.3% in the United States.22 The development 
of effective prophylactic pre-exposure vaccines against HBV 
and the combination with hepatitis B immunoglobulins for 
post-exposure prophylaxis dramatically reduced the incidence 
of HBV infection.23,24 In Taiwan, HCC incidence in children 
after universal vaccination against HBV reduced the number 
of cases from 0.70 to 0.35 per 100,000 children.25
The incidence of HCV also decreased after screening of 
blood donors in the 1990s, but due to the 20-year latency time 
from the acute infection to onset of cirrhosis and HCC, the 
impact of the reduction in HCV will not be observed before 
the year 2015. It is expected that the incidence of cases of 
HCV-related HCC will continue to decrease. An effective 
vaccine against HCV infection has not yet been developed due 
to the high mutation rate of the virus. For patients with chronic 
HBV or HCV infection, treatment with alpha interferon has 
been associated with lower incidence of HCC.26-28
Several studies performed in Western countries have 
demonstrated that 30% to 40% of HCC patients had no chronic 
HBV or HCV infection, suggesting the presence of other 
causes. Some of these patients had clinical or biochemical 
alterations compatible with NAFLD, such as obesity or 
metabolic syndrome. In population-based cohort studies in 
the United States, Scandinavia, Taiwan, and Japan, HCC was 
1.5 to 2.0 times more frequent in obese than in non-obese 
patients.29-32 Several case-control studies and some cohort 
studies have demonstrated that, on average, HCC is twice as 
likely to develop in individuals with diabetes mellitus type 2 than 
in non-diabetic patients.33,34 NAFLD, which is present in almost 
90% of obese individuals and in almost 70% of individuals with 
type 2 diabetes mellitus, appears to be a possible risk factor for 
HCC.35 Due to the limited data establishing a direct association 
between the progression of hepatic steatosis and HCC, the 
currently available estimates of risk are not clear. However, 
due to the high incidence of metabolic syndrome in Western 
countries, any increase, however small, in the risk of obesity or 
diabetes can result in a higher number of HCC cases.
The pathogenic mechanisms involved include lipid 
peroxidation and oxidative stress, production of free radicals as 
a precursor to tumor onset and progression; chronic activation 
of the inhibitor of kappa-beta kinase (IKK-b), which leads to 
inflammation; and hepatic fibrosis due to hyperinsulinemia 
and hyperglycemia.36
Aflatoxins, particularly aflatoxin B1 (AFB-1), are potent liver 
carcinogens produced by a fungus (Aspergillus flavus and A. 
parasiticus), common contaminants of stored grain.37 Gene 
mutation caused by AFB-1 at codon 249, exon 7 of the tumor 
suppressor gene TP53 (GC to TA transversion) was identified 
and positively correlated with exposure to aflatoxin in a 
meta-analysis comprising 49 studies.38,39 In addition, aflatoxins 
are synergistic with chronic HBV infection for the development 
of HCC.11
Hepatocellular carcinoma molecular pathways
The association between hepatocarcinogenesis molecular 
pathways and the risk factors associated with this condition 
is the object of investigation, aiming at adequate, personalized, 
and effective chemoprevention and treatment of HCC (Fig. 2).
Chronic HBV infection involves three distinct mediation 
mechanisms in hepatocarcinogenesis. The first mechanism 
involves integration of viral DNA into the host genome, 
inducing chromosome instability.40,41 The second proposed 
mechanism involves multiple genetic mutations by insertion, 
resulting in the integration of HBV genome at specific sites 
that can activate endogenous genes, for instance, RAR (retinoic 
acid receptor) b, cyclin A, and TRAP1.42-44 The third mechanism 
involves modulation of cell proliferation by viral protein 
expression, particularly HBV X protein (HBx) with 154 amino 
acids (16.5-kDa), which can transactivate or overexpress a 
variety of viral and cellular genes.44,45
Many studies have associated HBx with the malignant 
transformation process that occurs in HCC. Studies have 
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shown that HBx can coactivate the transcription process of 
some important cell and viral genes, thus coordinating the 
balance between cell proliferation and apoptosis.46,47 Cell 
promoters of genes associated with proliferation, such as 
interleukin 8 (IL-8), tumor necrosis factor (TNF), transforming 
growth factor (TGF-b1), and epidermal growth factor receptor 
(EGFR), as well as transcription factors, are activated with HBx 
transactivation.48,49
HBx also appears to be involved in the activation of 
signaling cascades involving the Ras/Raf/MAPK pathway, 
contributing to disregulation of cell cycle checkpoints,50 as well 
as to the activation of several oncogenes such as c-myc, c-jun 
and c-fos in the cytoplasm.51,52 Studies have also demonstrated 
two pathways by which HBx can activate the Wnt/b-catenin 
pathway, in collaboration with the proto-oncogene protein 
Wnt-1, through the stabilization of cytoplasmic b-catenin in 
HCC cells,53 or by activation of the extracellular signal-regulated 
kinase (Erk), which leads to phosphorylation, and in turn, to 
the inactivation of kinase-3b of glycogen synthesis (GSK-3b), 
stabilizing the b-catenin.54
Another alternative mechanism of Wnt activation in HCC 
is by the repression of E-cadherin by HBx in transcription, 
through the hypermethylation of E-cadherin promoter.55 
These mechanisms demonstrate the association of HBx 
with decreased expression of E-cadherin and b-catenin 
accumulation in the cytoplasm and/or nucleus, leading to 
increased activation of b-catenin.56  In the normal state, 
b-catenin is targeted for degradation by casein kinase Ia and 
GSK-3b.57 20% to 90% of all HCC have evidence of b-catenin 
activation, which has increased interest in the study of this 
pathway as a therapeutic target.58-60
Similarly to what occurs with several proteins codified 
by virus DNA, HBx can bind to p53, forming protein-protein 
complexes, and thus inactivating p53-dependent critical 
activities such as p53-mediated apoptosis,61  or even 
repressing TP53  transcription.62  These modulatory 
effects of HBx on p53 provide the basis for cell malignant 
transformation. In addition to this role in apoptosis, HBx 
can also contribute to tumorigenesis in HCC through the 
overexpression of the potent angiogenic factor of vascular 
endothelial growth factor (VEGF), demonstrated in studies 
under hypoxic conditions.63,64
Clinical and epidemiological studies attribute a higher 
degree of aggressiveness to HCV than to HBV, as there is a 
higher frequency of cases of HCC in patients with HCV-induced 
cirrhosis. In contrast to HBV, HCV is an RNA virus that is not 
integrated in the host genome; nevertheless, several virus-host 
interactions occur, which are believed to be responsible for 
the indirect hepatocarcinogenesis of this virus. The core 
protein of HCV is highly conserved and has been widely 
studied, as it is believed that it plays an important role in 
hepatocarcinogenesis through modulation of cell proliferation, 
apoptosis, and immune response. 
This core protein of HCV induces ROS formation through 
interaction with shock protein Hsp60, in addition to binding 
to p53, p73, and Rb protein.47,65 This interaction with tumor 
suppressor proteins appears to explain the fact that the protein 
is associated with p21WAF1 inhibition, leading to apoptosis 
inhibition and promoting cell cycle.47
The Raf1/MAPK and Wnt/b-catenin pathways are activated 
by the HCV core protein, while it also inhibits TGF-b pathway 
and activates TNF-a receptor and NF-kb pathway.58,66,67 Studies 
have also demonstrated that the frequency of the b-catenin 
gene mutation in HCC of patients with HCV is approximately 
twice as high when compared to other causes.68
It is known that chronic inflammation and infection are 
often associated with increased risk of cancer. Infections 
caused by HBV and HCV cause inflammation with production 
of free radicals, cytokines, and chemokines, resulting in 
DNA damage, cell proliferation, fibrosis, and angiogenesis. 
An example of a response to inflammatory stress is the 
p53 pathway itself.69 Free radicals, such as reactive oxygen 
or nitrogen species, can directly damage DNA and proteins, 
and/or indirectly damage these macromolecules through lipid 
peroxidation.
Increasing evidence indicates that nitric oxide (NO), an 
important signaling and bioregulation molecule catalyzed 
by the NOS enzyme family, plays an important role in 
carcinogenesis.70,71 In chronic hepatitis, the overexpression of 
proinflammatory cytokines such as TNF-a, INF-g, and IL-1, lead 
to increased concentrations of NO in human hepatocytes.72 
NO can cause DNA damage and induce a stress response 
through p53 anti-carcinogenic pathway or cause mutations in 
cancer-related genes, such as TP53.70
The mutational inactivation of TP53 has been widely 
described as one of the molecular mechanisms involved in HCC 
pathogenesis, especially in geographic areas where exposure to 
aflatoxin B1 (AFB1) is prominent.39,73,74 However, and although 
the G»T mutation in codon 249 of the P53 gene is closely 
related to the AFB1 exposure, most HCC cases show absence 
of TP53 mutations, so that this inactivation is associated with 
other mechanisms, such as interactions with viral proteins.75
HCC has a high degree of genetic heterogeneity, suggesting 
that multiple molecular pathways may be involved in the 
genesis of hepatocellular cancer subsets. Understanding the 
molecular and cellular bases of neoplastic transformations that 
occur in the liver allow for the development of better strategies 
for the prevention of and/or more effective treatments for HCC. 
Symptoms
HCC symptoms are not specific, generally indicate advanced 
HCC, and are more directly related to liver function impair-
ment. There may be abdominal pain (between 40% and 
60%), which may indicate spontaneous bacterial peritonitis; 
palpable mass in the abdomen on the right (23%); abdominal 
distension (45%) loss of appetite (45%); jaundice (16%); 
ascites (26%); weight loss (29%); malaise (60%); andsigns of 
hepatic encephalopathy, from drowsiness to coma, and 
gastrointestinal bleeding76 (7%).
Pathology and diagnosis
The prognosis for patients with HCC is generally dismal. 
Survival varies from a few weeks to a year, depending on the 
extent of tumor involvement and other prognostic factors. 
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HCC may display four degrees of differentiation (according 
to the classification of Edmondson and Steiner, 1954) and five 
different histological types:
• sclerosing HCC;
• fibrolamellar carcinoma (which is the most straightforward 
to undergo surgical resection, thus yielding a better prog -
nosis);
• cholangiocellular carcinoma;
• hepatocholangiocarcinoma;
• hepatoblastoma (more common in children).
Malignant transformation of hepatocytes in HCC is a 
gradual process associated with genetic mutations, allelic loss, 
epigenetic alterations, and disruption of cellular and molecular 
pathways. The phenotypic expression of these alterations may 
manifest as precursor lesions that accompany HCC, called 
dysplastic nodules.77,78 These nodules are distinct from benign 
regenerative nodules associated with cirrhosis due to their 
high proliferative index and clonality. 
The International Working Party of Terminology of the 
World Congress of Gastroenterology classified the dysplastic 
nodules, which are distinct nodular lesions larger than 
5 mm in diameter, as low-grade dysplastic nodules (LGDN) 
and high-grade dysplastic nodules79 (HGDN). LGDN nodules 
show only mild dysplasia and do not express any relation to 
malignancies. HGDN nodules, in turn, are characterized by 
higher cell density (small-cell lesions) than the surrounding 
tissues, exhibiting characteristic formations such as “nodule 
inside nodule”, resembling well-differentiated HCC both at 
radiological and pathological assessment.80,81
The distinction between HGDN nodules and early-stage 
HCC is a challenge yet to be resolved. A panel of three 
immunohistochemical markers of malignant transformation, 
such as heat shock protein (HSP) 70, glutamine synthetase, and 
glypican-3 has been used to differentiate them.82,83 Additio-
nally, molecular data based on quantitative gene expression 
profiles with the LYVE-1 gene, E-cadherin, and survivin allow 
for a reliable diagnosis of early-stage HCC.84
The diagnosis of HCC can be attained through imaging 
tests, tumor markers (blood test), and anatomopathological 
examination (biopsy). As there is not always an increase 
in tumor markers and biopsy may not be possible (due to 
clotting deficiency caused by liver failure, to ascites, or to 
access difficulty due to tumor location) or recommended 
(there is a theoretical risk, from anecdotal reports, of tumor 
dissemination along the needle trajectory), the diagnosis 
of HCC can be achieved by imaging assessment presenting 
typical lesion and tumor marker increase, or by the presence 
of typical image in two different types of imaging assessment. 
The guidelines for the diagnosis of HCC76 suggest that 
patients with cirrhosis and radiologically-detected mass do 
not need biopsy confirmation of HCC diagnosis. Criteria for 
this diagnosis are: lesion of at least 2 cm in diameter with 
typical vascular patterns in dynamic images obtained from 
computed tomography (CT), ultrasound with contrast, or 
magnetic resonance imaging (MRI) showing enhancement in 
the arterial phase with rapid clearance of contrast in the portal 
phase. 
For lesions 1-2 cm in diameter, at least two dynamic 
imaging studies are needed to highlight the typical features of 
HCC. Lesions < 1 cm in diameter should be followed by contrast 
ultrasound every 3-6 months. These guidelines are supported 
by the high incidence of regenerative nodules in cirrhotic livers 
that remain stable for many years, but can undergo malignant 
transformation to HCC due to changes in vascular supply, with 
shunting of blood from the portal vein to the hepatic artery 
and consequent increase in size. A percutaneous biopsy of 
liver injury in cirrhotic patients increases the risk of bleeding, 
dissemination of tumor cells, and false negative results due to 
inaccurate radiological location, particularly with small lesions. 
Levels of serum alpha-fetoprotein (AFP), a glycoprotein 
normally produced by the fetal liver and yolk sac, can 
be elevated with the development of HCC. AFP levels are 
particularly indicative if > 500 mg/L85,86 (normal values 10 to 
20 mg/L), although 20% of HCCs are not associated with high 
serum AFP levels, and moderate increases in AFP can be found 
in other conditions such as active hepatitis of any etiology 
(virus-related, drug-related, autoimmune disease), pregnant 
women carrying fetuses with abnormalities such as spina 
bifida, and patients with germ-cell or gastric cancer. Serum 
AFP levels have also been used to enhance the sensitivity of 
non-contrast ultrasound when screening individuals at high 
risk for HCC.87,88
Staging and treatment
Due to the close association between HCC and cirrhosis, 
prognosis of individual cases depends on cirrhosis severity 
and the degree of malignant involvement of HCC. Most staging 
criteria for HCC prognosis incorporate elements on tumor 
extent and cirrhosis severity; however, the tumor-node-
metastasis (TNM) staging system includes size, multi focality, 
vascular involvement, and distant metastases, but does not 
include the characteristics of cirrhosis.89
For the prognosis of patients with cirrhosis, the parameters 
of chronic liver disease evaluation, such as those used in the 
Child-Pugh classification, have been incorporated to most HCC 
classification criteria, including the Cancer of the Liver Italian 
Program score (CLIP), the Japan Integrated Staging Score (JIS), 
the Chinese University Prognostic Index (CUPI) and the French 
Prognostic Classification.90-93
Okuda classification 
The classification of Okuda (1985) aims to predict the mean 
survival of patients with HCC not submitted to any type 
of minimally effective therapy, but submitted to medical 
treatment or hepatectomy. Based only on four relatively simple 
and objective parameters (although it is sometimes difficult to 
determine whether the tumor proportion in relation to the total 
liver size is greater or less than 50%), tumor stage is defined, 
along with its estimated prognosis in weeks. The caveat 
regarding this classification is that the clinical treatments 
have considerably improved since 1985, particularly with the 
emergence of new chemotherapeutic agents, improvements in 
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chemoembolization techniques and percutaneous treatments, 
and with the aid of new instruments such as argon scalpels 
and Yag-laser, in addition to the improvement in hepatectomy 
techniques. The classification remains important regarding the 
prognosis of untreated patients as a basis for comparison with 
the currently available treatments.94,95
The CLIP classification system encompasses the Child-Pugh 
classification, which assesses liver function, affected liver 
fraction (as in the Okuda classification), serum levels of 
alpha-fetoprotein, and hepatic vessel infiltration by cancer, 
especially the portal vein. With the obtained score, it is 
possible to compare the expected life expectancy in similar 
conditions.96
The Barcelona Clinic Liver Cancer (BCLC) is an internatio-
nally standardized system recommended by the American 
Association for the Study of Liver Diseases (AASLD) and 
the European Association for the Study of the Liver (EASL), 
and is based solely on clinical parameters.76,97 Recently 
(2012) the EASL, together with the European Organization 
for Research and Treatment of Cancer (EORTC), published 
a set of clinical guidelines for surveillance, diagnosis, and 
therapeutic strategies for HCC, thus updating the panel of 
recommendations proposed in 200198 and used to date.99
The BCLC system classifies HCC as very early, early, 
intermediate, advanced, and terminal disease, based on the 
Child-Pugh criteria, functional status, tumor size, multifocality, 
and presence of portal vein invasion. Patients with very 
early and early stages are amenable to curative treatment 
modalities, including surgical resection, liver transplantation, 
percutaneous ethanol injection, or radiofrequency ablation. 
Patients with intermediate-stage HCC are amenable 
to treatment by chemoembolization. For patients with 
advanced-stage HCC, which represent a large number of 
diagnosed cases, the recommended treatments include several 
tyrosine kinase inhibitors or participation in phase III and IV 
clinical trials, considering that the aforementioned treatments 
are rarely effective. Critically-ill patients are not usually 
considered for specific treatment and palliative treatment is 
indicated for symptom control.
Early-stage HCC presents as a small nodule with a diameter 
< 2 cm and can be classified into two types: small, nodular-type 
HCC, which is well defined and sometimes encapsulated; or 
indistinct (vague) nodular-type that is poorly defined and has 
no clear borders.100,101 Dysplastic nodules and early HCC are 
usually asymptomatic and are usually incidental findings 
on radiographic studies or detected as a result of screening 
procedures. Early HCC can be indolent or slow-growing (up 
to one year), until it undergoes rapid tumor progression. In 
these early stages, HCC gradually progresses with increase 
in tumor volume, followed by invasion of the portal vein 
branches, extending to the main portal vein. The portal 
vein invasion is generally accompanied by a rapid increase 
in serum concentrations of AFP, even with no alterations in 
size of the primary liver tumor. The tumor can also directly 
invade the hepatic vein branches and the intrahepatic inferior 
vena cava, spreading to the superior vena cava or the right 
atrium as tumor thrombus. Hepatic artery invasion is much 
less common. 
HCC dissemination occurs primarily through the blood to 
the lungs, bones, and brain at later stages. These metastatic 
lesions are typically hypervascular, as is the primary tumor, 
and predispose to bleeding (intracranial hemorrhage or 
hemoptysis). Bone metastases can be single or multiple and 
can produce isolated symptoms such as cranial nerve or 
peripheral nerve compression. 
The standardized assessments for the detection of 
HCC metastasis are CT with contrast of the skull, chest, 
abdomen, and pelvis, as well as bone scintigraphy . Dynamic 
acquisitions with contrast are generally not necessary, but if 
performed, they can demonstrate arterial hypervascularity of 
the metastatic lesions similar to that of the primary tumor. 
Positron emission tomography (PET) has not shown sufficient 
Drug Drug type Molecular target Affected signaling pathway Approval (EMEA and FDA)
Sorafenib TC inhibitor VEGFR, PDGFR, RAF VEGFR, PDGFR, RAS/MAPK Approved
Sunitinib TC inhibitor VEGFR, PDGFR, c-kit VEGFR, PDGFR, c-kit Not approved (undergoing 
phase II 
or III trials)
Bevacizumab Monoclonal antibody 
to the ligand
VEGFR VEGFR
Cetuximab Monoclonal antibody 
to the ligand
EGFR EGFR
Trastuzumab Monoclonal antibody 
to the receptor
Her-2/neu Her-2/neu
Erlotinib TC inhibitor EGFR EGFR
Gefitinib TC inhibitor EGFR EGFR
Lapatinib TC inhibitor Her-2/neu Her-2/neu
Rapamycin ST kinase inhibitor mTOR PIK3/Akt/mTOR
Everolimus ST kinase inhibitor mTOR PIK3/Akt/mTOR
XL-765 ST kinase inhibitor PI3K PIK3/Akt/mTOR  
Akt, protein kinase B; EMEA, European Medicines Agency; FDA, Food and Drug Administration; MAPK, mitogen-activated protein kinase; 
mTOR, mammalian target of rapamycin; PDGFR, platelet-derived growth factor receptor; PIK3, phosphatidylinositol 3-kinase; ST, serine/
threonine; TC, tyrosine kinase; VEGFR, vascular endothelial growth factor receptor.
Table 1 – Targeted therapies in hepatocellular carcinoma.108-113
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reliability to justify its inclusion in routine examinations in 
HCC staging.102
Multiple tumors can arise in cirrhotic liver, particularly 
with chronic HCV infection, or may represent liver metastases 
consequent to thrombosis of the portal vein, from the primary 
tumor and hematogenous spread to the liver. 
The clinical and genetic heterogeneity of this disease 
dictates the fact that there is little effective therapeutic 
response in HCC. Therapy directed at molecular targets, 
either genes or their receptors, aims to inactivate activated 
oncogenes, recover tumor suppressor genes, or any molecule 
or gene involved in the development of HCC, thereby repairing 
errors or abnormal functions or biological behavior. Recently, 
many genome-based molecules have been candidates for 
targeted therapy. They have been discovered by microarray 
studies, at the analysis of epigenetic aberrations of the total 
genome, from high-performance sequencing systems. Some 
genes or target molecules currently in study are VEGFR, EGFR, 
DDEFL, VANGL1, WDRPUH, Ephrin-A1, GPC3, and PFTK1, 
among others.103,104 Many of these molecules for targeted 
therapy, such as monoclonal antibodies, small molecules, 
and antisense molecules are now in phase II and III clinical 
trials, with promising data at this time. At the moment only 
sorafenib, a multikinase VEGFR and RAS kinase inhibitor, has 
been approved by the Food and Drug Administration and by 
the European Medicines Agency104,105 (EMEA) (Table 1).
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